2022
DOI: 10.1016/j.intimp.2021.108505
|View full text |Cite
|
Sign up to set email alerts
|

Preparation of antibodies against TXR1 and construction of a new DNA tumor vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 32 publications
0
3
0
Order By: Relevance
“…In clinical practice, therapeutic agents to suppress tumors can be designed by identifying molecular targets known to have oncogenic effects [ 31 ] . With this in mind, we analyzed apaQTL-genes in cancer signaling pathways, somatic mutations and immune infiltration.…”
Section: Discussionmentioning
confidence: 99%
“…In clinical practice, therapeutic agents to suppress tumors can be designed by identifying molecular targets known to have oncogenic effects [ 31 ] . With this in mind, we analyzed apaQTL-genes in cancer signaling pathways, somatic mutations and immune infiltration.…”
Section: Discussionmentioning
confidence: 99%
“…193 Others pursue DNA-based vaccine approaches to fight drug resistance in cancer. 194 Adenoviral-based drug delivery is an option to deliver nucleic acids (reviewed by Sakurai et al 195 ); however, repeated administration could fail to induce www.moleculartherapy.org…”
Section: Review Conclusion and Outlookmentioning
confidence: 99%
“…These molecules are eliminated from the blood by adding different neutral salts (ammonium sulphide, sodium chloride, and sodium sulphide). The solubility of proteins decreases with increasing salt concentration [1]. At very high salt concentration, proteins become insoluble and precipitates.…”
mentioning
confidence: 99%
“…The euglobulin fraction of immunoglobulin is precipitated for storage. 50-60% of Ammonium sulfate used for the preparation of main IgM as shown in fig (1) [2]. Potassium phosphate buffer in 60 mM concentration is added in antiserum (20 mL) for dilution and incubated at 4°C, at pH 7.0 for 24 hours.…”
mentioning
confidence: 99%